Press Release
19 November 2026 07:30:00 CET

Neola Medical CEO Discusses Q3 2026 Progress and Strategic Priorities in Redeye Interview

Watch Neola Medical's latest interview with Redeye Equity Research Analyst Gustaf Meyer, where CEO Hanna Sjöström discusses the key developments from Q3 2026 and the company's priorities ahead.

The interview highlights the FDA Breakthrough Device Designation granted in September, the subsequent enrollment in the FDA TAP Pilot Program, and how these milestones strengthen Neola Medical's regulatory pathway in the U.S.

Hanna Sjöström also shares insights into ongoing preclinical development, preparations for the U.S. clinical program, and the next steps toward market authorization.

Watch the full interview here:
https://player.vimeo.com/video/1247936770

The Q3 2026 report is available at www.neolamedical.com.

For further information, contact:
Hanna Sjöström, CEO
e-mail: hanna.sjostrom@neolamedical.com

David Folkesson, CFO
email: david.folkesson@neolamedical.com

About Neola Medical
Neola Medical AB (publ) develops an innovative medical technology device for non-invasive, continuous lung monitoring and real-time alerts of potentially life-threatening lung collapse in preterm born babies. By enabling instant detection, the technology aims to support earlier intervention, improve clinical decision-making, enhance long-term outcomes, and ultimately contribute to saving lives. The patented, cutting-edge technology was developed at Lund University in Sweden and is based on near-infrared light measurements in the lungs. Neola Medical builds on Sweden's longstanding legacy of medical technology innovation and contributions to global health care. Neola Medical was founded in 2016 and is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more at www.neolamedical.com. The company's Certified Adviser is FNCA Sweden AB.

Attachments
Neola Medical CEO Discusses Q3 2026 Progress and Strategic Priorities in Redeye Interview